首页> 外文期刊>Catheterization and cardiovascular interventions: Official journal of the Society for Cardiac Angiography & Interventions >Stenting of long coronary artery lesions: initial angiographic results and 6-month clinical outcome of the micro stent II-XL.
【24h】

Stenting of long coronary artery lesions: initial angiographic results and 6-month clinical outcome of the micro stent II-XL.

机译:长期冠状动脉病变的支架置入术:微血管支架II-XL的初步血管造影结果和6个月的临床结果。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

To evaluate the results of long Micro Stent II (MS-XL) implantations, 119 MS-XLs were implanted in 102 patients (age, 62.83 years). Nineteen stents (16%) were implanted in saphenous vein grafts; 100 stents (84%) were implanted in native coronary arteries. Twenty-five patients (25%) were treated because of acute myocardial infarction (AMI); 30 patients (29%) because of unstable angina or angina class IV, and 47 patients (46%) because of stable angina. Eighty-six de novo lesions (84%) and 16 restenotic lesions (16%) were treated. Indications for stent implantation include elective, 61 patients (60%); suboptimal balloon angioplasty result, 22 patients (21%); and bailout after balloon angioplasty, 19 patients (19%). Because of residual thrombus after stenting, 27 patients (26%) received abciximab. All patients received ticlopidin for 28 days and acetylsalicylic acid. One hundred and seventeen MS-XLs (98%) were implanted successfully. Additional (shorter) MS-II were implanted in 40 patients (39%). The stented segment length was 45 +/- 20 mm. The minimum lumen diameter increased from 0.5 +/- 0.5 mm before to 2.7 +/- 0.5 mm after stent implantation. The acute gain was 2.2 +/- 0.4 mm. Early clinical events (<4 weeks) include death, 3 (3%); subacute stent thrombosis, 1 (1%); non-Q-wave infarction, 2 (2%); CABG, 1 (1%); vascular complications, 2 (2%). Late clinical events (<6 months) include acute myocardial infarction, 5 (5%); reintervention, 6 (6%); CABG, 1 (1%). The procedural success rate was 88%, and the event free survival at 6 months was 76%. Stenting of long lesions with the MS-XL was successful and associated with an acceptable complication rate. Cathet. Cardiovasc. Intervent. 48:105-112, 1999. Copyright 1999 Wiley-Liss, Inc.
机译:为了评估长期Micro Stent II(MS-XL)植入的结果,在102例患者(年龄62.83岁)中植入了119枚MS-XL。大隐静脉移植物中植入了19个支架(占16%)。 100个支架(占84%)植入了天然冠状动脉。急性心肌梗死(AMI)接受治疗的患者有25名(25%); 30例(29%)由于不稳定的心绞痛或IV级心绞痛,47例(46%)由于稳定的心绞痛。治疗了86例从头病变(84%)和16例再狭窄病变(16%)。支架植入的适应症包括选择性的61例患者(60%);结果不理想的球囊血管成形术22例(21%);和球囊血管成形术后的救助19例(19%)。由于支架置入后残留血栓,所以27例(26%)患者接受了阿昔单抗治疗。所有患者均接受了28天的噻氯匹定和乙酰水杨酸治疗。成功植入了117个MS-XL(98%)。另外(较短)的MS-II植入了40例患者中(39%)。支架段长度为45 +/- 20 mm。最小管腔直径从支架植入后的0.5 +/- 0.5 mm增加到植入支架后的2.7 +/- 0.5 mm。急性增益为2.2 +/- 0.4mm。早期临床事件(<4周)包括死亡,3(3%);亚急性支架血栓形成,1(1%);非Q波梗死,2(2%); CABG,1(1%);血管并发症2(2%)。晚期临床事件(<6个月)包括急性心肌梗塞5例(5%);再干预,6(6%); CABG,1(1%)。手术成功率为88%,6个月无事件生存率为76%。 MS-XL可以成功固定长病变,并具有可接受的并发症发生率。 the。心血管干预。 48:105-112,1999。版权所有1999 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号